Recent Findings from Sanliurfa Mehmet Akif Inan Training and Research Hospital Highlight Research in Bone Diseases and Conditions (Long-acting Zoledronic Acid: Once-yearly Administration And Efficacy Evaluation in Myeloma Bone Disease).

A recent study conducted at Sanliurfa Mehmet Akif Inan Training and Research Hospital focused on the preventive effect of long-acting zoledronic acid on new vertebral fractures in multiple myeloma patients with osteoporosis and/or vertebral fractures. The study found that the 5 mg formulation of zoledronate effectively prevented new fractures in all myeloma patients, regardless of their initial condition. This treatment approach was not only effective but also more cost-efficient compared to other treatment regimens, making it a promising option for myeloma patients. [Extracted from the article]